IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 125 filers reported holding IMMUNOVANT INC in Q1 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,343,381 | -50.4% | 34,993 | -75.5% | 0.00% | 0.0% |
| Q2 2023 | $2,706,678 | +333.9% | 142,682 | +254.7% | 0.00% | – |
| Q1 2023 | $623,827 | +9.9% | 40,221 | +25.8% | 0.00% | – |
| Q4 2022 | $567,432 | +283.4% | 31,968 | +20.2% | 0.00% | – |
| Q3 2022 | $148,000 | +97.3% | 26,587 | +37.5% | 0.00% | – |
| Q2 2022 | $75,000 | -42.3% | 19,330 | -18.1% | 0.00% | – |
| Q1 2022 | $130,000 | -89.6% | 23,608 | -83.9% | 0.00% | -100.0% |
| Q4 2021 | $1,250,000 | -0.9% | 146,637 | +1.1% | 0.00% | 0.0% |
| Q3 2021 | $1,261,000 | -35.3% | 145,089 | -21.3% | 0.00% | 0.0% |
| Q2 2021 | $1,950,000 | -24.0% | 184,457 | +15.3% | 0.00% | 0.0% |
| Q1 2021 | $2,566,000 | +78.2% | 159,946 | +413.0% | 0.00% | 0.0% |
| Q4 2020 | $1,440,000 | +94.1% | 31,181 | +47.9% | 0.00% | 0.0% |
| Q3 2020 | $742,000 | -74.2% | 21,076 | -82.2% | 0.00% | -50.0% |
| Q2 2020 | $2,875,000 | – | 118,097 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |